Actinium Pharmaceuticals Announced Sierra Trial Results For Iomab-b For Relapsed/Refractory Acute Myeloid Leukemia In An Oral Presentation At The European Hematology Association 2023 Congress; BLA Filing For Iomab-B Expected By End Of 2023
Portfolio Pulse from Benzinga Newsdesk
Actinium Pharmaceuticals announced Sierra trial results for Iomab-B in treating relapsed/refractory acute myeloid leukemia at the European Hematology Association 2023 Congress. The company expects to file a BLA for Iomab-B by the end of 2023.
June 12, 2023 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Actinium Pharmaceuticals' Sierra trial results for Iomab-B show promise in treating acute myeloid leukemia, with a BLA filing expected by end of 2023.
The announcement of positive Sierra trial results for Iomab-B indicates potential success in treating acute myeloid leukemia. The expected BLA filing by the end of 2023 suggests regulatory progress, which could positively impact Actinium Pharmaceuticals' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100